(Q84458225)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22733106%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

title

Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22733106%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22733106%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

René-Olivier Casasnovas

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22733106%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Thierry J Molina

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22733106%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Louis Terriou

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22733106%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Corinne Haioun

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22733106%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

H Tilly

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22733106%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

F Morschhauser

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22733106%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

P Feugier

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22733106%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

F Jardin

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22733106%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

B Coiffier

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22733106%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

publication date

26 June 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22733106%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22733106%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22733106%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22733106%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

252-255

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22733106%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2012.172

6 February 2020

exact match

0 references

cites work

Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.172

7 January 2021

Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.172

7 January 2021

Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.172

7 January 2021

Lenalidomide for the treatment of B-cell malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.172

7 January 2021

Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.172

7 January 2021

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.172

7 January 2021

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.172

7 January 2021

Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.172

7 January 2021

Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.172

7 January 2021

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.172

7 January 2021

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2012.172

7 January 2021